JPRN-jRCT2080223396已完成3 期
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 408
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Cytologically or histologically confirmed diagnosis of MDS or CMML according to the 2008 World Health Organization (WHO) classification.
- •- ECOG PS of 0-2.
- •- Subjects with previously treated MDS or CMML, defined as prior treatment with at least one hypomethylating agent (HMA; azacitidine and/or decitabine) for intermediate or high risk MDS or CMML whose disease progressed or relapsed as follows:
- •a. Subject received HMA for at least 6 cycles and was still transfusion dependent (as defined in 5b below).
- •b. Subject had disease progression prior to Cycle 6 defined as 50% or more increase in bone marrow blasts from pretreatment levels to more than 5%, or 2 g/dL or more reduction of Hgb from pretreatment levels with transfusion dependence after at least 2 cycles of HMA.
- •- Subjects must have either:
- •a. Bone marrow blasts more than 5% at randomization, OR
- •b. Transfusion dependence, defined as having had transfusion (in the setting of active disease) of 2 or more units of RBC or platelets within 8 weeks prior to randomization.
- •- Creatinine clearance or glomerular filtration rate 30 mL/min or more estimated by the Cockroft-Gault (C-G) or other medically acceptable formulas such as MDRD or CKD-EPI.
- •- Women of childbearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of childbearing potential and men with female partners of childbearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child while receiving treatment with guadecitabine, LDAC, or IC and for at least 3 months after completing treatment.
排除标准
- •- Subjects who have been diagnosed as having acute myeloid leukemia (AML) with peripheral blood or bone marrow blasts of 20% or more.
- •- Subjects who may still be sensitive to repeated treatment with decitabine or azacitidine.
- •- Prior treatment with guadecitabine.
- •- Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
- •- Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
- •- Treated with any investigational drug within 2 weeks of the first dose of study treatment.
- •- Total serum bilirubin more than 2.5 ULN (except for subjects with Gilbert's Syndrome for whom direct bilirubin is less than 2.5 ULN), or liver cirrhosis or chronic liver disease Child-Pugh Class B or C.
- •- Known active human immunodeficiency virus, hepatitis B virus, or hepatitis C virus infection.
- •- Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol.
- •- Refractory congestive heart failure unresponsive to medical treatment, active infection resistant to all antibiotics, or advanced non-MDS associated pulmonary disease requiring more than 2 liters per minute (LPM) oxygen.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Study to Compare Avelumab Given Alone or Given in Combination with Pegylated Liposomal Doxorubicin Compared to Pegylated Liposomal Doxorubicin Given Alone Patients with Platinum-Resistant/Refractory Ovarian CancerOvarian CancerMedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-003091-77-PLPfizer Inc., 235 East 42nd Street, New York, NY 10017550
进行中（未招募）
1 期
A clinical trial to assess and compare overall survival (OS) between guadecitabine and treatment choice (TC) in adults with previously treated acute myeloid leukemia (AML)Acute Myeloid Leukemia (AML)MedDRA version: 20.0Level: HLTClassification code 10024291Term: Leukaemias acute myeloidSystem Organ Class: 100000004851EUCTR2015-005256-97-BEAstex Pharmaceuticals, Inc.300
进行中（未招募）
1 期
A Phase 3 Study to Compare Avelumab Given Alone or Given in Combination with Pegylated Liposomal Doxorubicin Compared to Pegylated Liposomal Doxorubicin Given Alone Patients with Platinum-Resistant/Refractory Ovarian CancerOvarian CancerEUCTR2015-003091-77-NLPfizer Inc., 235 East 42nd Street, New York, NY 10017550
进行中（未招募）
1 期
A clinical trial to compare guadecitabine (SGI-110) to other available therapies in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have previously been treated with hypomethylating agentsEUCTR2015-005257-12-DKAstex Pharmaceuticals, Inc.408
已完成
3 期
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemiaacute myeloid leukemiaJPRN-jRCT2080223674Otsuka Pharmaceutical Co., Ltd.400